Financial Performance - Consolidated YOY comparable revenue trends improved in Q1 2025[9] - Adjusted free cash flow significantly increased YOY, reaching $45 million in Q1 2025, compared to $17 million in the same period last year[9, 19] - Adjusted EBITDA was $76 million[18, 23] - Adjusted operating income was $54 million[18, 23] Business Segments - Office Depot's same store sales improved by 500 basis points YOY[9] - Veyer's revenue from third-party customers grew strongly, up 89% to $17 million in Q1 2025[9, 34] - ODP Business Solutions' adjacency categories accounted for 44% of the division's total revenue[28] Strategic Initiatives - The company is executing the "Optimize for Growth" plan, expecting a $380 million uplift in EBITDA and $1.3 billion in total value creation[12] - The company closed 9 retail store locations in Q1 2025, incurring $48 million in restructuring costs[12] - The company is expanding into the hospitality market, a $16 billion addressable market[10, 11] Financial Position - The company has a strong liquidity position, with $653 million in total available liquidity, including $185 million in cash and cash equivalents[38]

Financial Performance - Net sales for Q3 totaled $374.6 million, a 12% year-over-year decrease, or a 10% decrease excluding AT&M[24, 26] - Medical net sales in Q3 were $115 million, up 2% compared to last year, representing 31% of total company sales[13, 15] - Automotive net sales were $173 million, a 14% decrease compared to last year, representing 46% of total company sales[17, 20] - Industrial net sales were $86 million, down 15% year-over-year excluding AT&M, representing 23% of total company sales[21, 23] - Adjusted selling & administrative expense totaled $11.2 million, a 24% reduction compared to last year, representing 3.0% of sales[33] - Adjusted operating income was $15.7 million, or 4.2% of net sales[37] Strategic Initiatives - The company is reiterating fiscal year 2025 guidance, expecting sales and operating income to be at the high-end of the range[8, 53] - A new manufacturing facility in Indianapolis focused on the medical industry is being added to expand presence as a medical CMO[8, 16] - Borrowings were reduced by $116 million, or 40%, from the beginning of the fiscal year, with short-term liquidity available totaling $304.6 million[50] Other - The gross margin rate in Q3 was 7.2%, a 70 bps decline compared to last year[27, 29]

Investor Presentation May 2025 Safe Harbor This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements made herein that are not statements of historical fact, including statements about Radware's plans, outlook, beliefs, or opinions, are forward-looking statements. Generally, forward-looking statements may be identified by words such as "believes," "expects," "anticipates," "intends," "estimates," "plans," and similar exp ...

FIRST QUARTER 2025 EARNINGS CONFERENCE CALL FORWARD LOOKING STATEMENTS Some statements in this release, which are not historical facts, are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements about Arcosa's estimates, expectations, beliefs, intentions or strategies for the future. Arcosa uses the words "anticipates," "assumes," "believes," "estimates," "expects," "intends," "forecasts," "may," "will," "should," "guid ...

An International Alternative Asset Manager FIRST QUARTER 2025 INVESTOR PRESENTATION TRINITYCAPITAL.COM NASDAQ: TRIN FORWARD-LOOKING STATEMENTS | DISCLAIMER Trinity Capital Inc. (the "Company") cautions that this presentation may contain forward-looking statements that are based on current expectations and assumptions about future events, and which are not based in historical fact. The forward-looking statements in this presentation are based on current conditions as of the date of this presentation, and inc ...

Financial Performance - Q3 2025 - Net sales reached $76 million[18], a decrease of 10% compared to Q3 FY24[20] - Adjusted EBITDA amounted to $75 million[18], down from $117 million in Q3 FY24[20] - Adjusted diluted net income per share was $030[18], a decrease from $050 in Q3 FY24[20] Financial Performance - YTD Q3 2025 - YTD net sales totaled $2047 million[22], a 24% decrease from FY24[22] - YTD Adjusted EBITDA was $149 million[22], down from $386 million in FY24[22] - YTD Adjusted Diluted Net Income per Share was $053[22], down from $112 in FY24[22] Balance Sheet & Capital Allocation - The company maintains a strong financial position with approximately $67 million in cash and investments and no debt[18] - The company returned $5 million of capital YTD through a share repurchase program[18] - The company authorized a $50 million share repurchase program in July 2023, with approximately $30 million still available[26] Fiscal Year 2025 Guidance - The company refines fiscal 2025 guidance with net sales of approximately $275 million[18] - The company projects adjusted EBITDA of approximately $20 million[18] - The company anticipates adjusted earnings per share of approximately $071[18]

Changes to Key Metrics Q1 2025 Primer 1 Change of Metric from Transacting Professionals to Active Pros A key sign of Pro engagement on our platform is Pros making themselves available to be presented to homeowners for particular Service Requests and paying for the corresponding Leads if selected by the homeowner. We've redesigned the metric - Average Monthly Active Pros - to best capture that activity. The current Transacting Professional metric is focused on whether a Pro has generated revenue during the q ...

TPG has declared a quarterly dividend of $0.41 per share of Class A common stock to holders of record at the close of business on May 19, 2025, payable on June 2, 2025. Conference Call TPG will host a conference call and live webcast at 11:00 am ET. It may be accessed by dialing (800) 245-3047 (US toll-free) or (203) 518-9765 (international), using the conference ID TPGQ125. The number should be dialed at least ten minutes prior to the start of the call. A simultaneous webcast will also be available and can ...

Business Highlights - BeiGene's Q1 2025 execution sets a strong foundation for the year, focusing on hematology franchise leadership, pipeline advancement, and superior financial performance[11] - Brukinsa is now the U S revenue leader among BTKis, with over 200,000 patients treated globally[17] - BeiGene has launched Brukinsa in Japan and it is now approved in 75 markets, with 11 new or expanded reimbursements including in Japan, EU, and Brazil[21] - Enrollment is complete in the Phase 3 CELESTIAL-TNCLL trial for Sonrotoclax, with global filing expected in R/R MCL in H2 2025[23] - BeiGene achieved GAAP profitability in Q1 2025, with GAAP Operating Income of $11 million compared to a loss of $261 million in Q1 2024[40] Financial Performance - Total revenue for Q1 2025 increased by 49% year-over-year, reaching $1.117 billion, compared to $752 million in Q1 2024[93, 95] - Net product revenue in Q1 2025 was $1.109 billion, a 48% increase from $747 million in Q1 2024[95, 96] - Brukinsa revenue in Q1 2025 reached $792 million, a 62% increase from $489 million in Q1 2024[95] - Tevimbra revenue in Q1 2025 was $171 million, an 18% increase from $145 million in Q1 2024[95] - GAAP earnings per ADS was $0.01 in Q1 2025, compared to a loss of $2.41 in Q1 2024[96]

Financial Performance - Azenta's Q2 2025 revenue reached $143 million, demonstrating a 5% year-over-year (YoY) growth on a reported basis and 6% on an organic basis[10] - The company's Non-GAAP EPS stood at $005[10] - Adjusted EBITDA was reported at 100%, reflecting a 400 bps YoY margin expansion[10,11] - Free cash flow generation amounted to $7 million, inclusive of B Medical[10] Segment Performance - Sample Management Solutions (SMS) experienced an 8% YoY organic growth[10,16] - Multiomics segment saw a 3% YoY organic growth[10,14] - Within SMS, Consumables and Instruments (C&I) showed a significant 22% growth[20] - Next-Generation Sequencing (NGS) within Multiomics grew by 20%, driven by double-digit volume growth[21] Balance Sheet and Cash Flow - The company holds a strong cash balance of $540 million, including B Medical, with no outstanding debt[10] - Cash flow from operations was $14 million[32] Fiscal Year 2025 Guidance - The company anticipates organic revenue growth of 3% to 5% YoY for fiscal year 2025[38] - Expects 300bps of Adjusted EBITDA margin expansion[39]